KR101781665B1 - 티아졸리딘디온 화합물을 위한 신규한 합성법 - Google Patents

티아졸리딘디온 화합물을 위한 신규한 합성법 Download PDF

Info

Publication number
KR101781665B1
KR101781665B1 KR1020127030070A KR20127030070A KR101781665B1 KR 101781665 B1 KR101781665 B1 KR 101781665B1 KR 1020127030070 A KR1020127030070 A KR 1020127030070A KR 20127030070 A KR20127030070 A KR 20127030070A KR 101781665 B1 KR101781665 B1 KR 101781665B1
Authority
KR
South Korea
Prior art keywords
alkyl
aliphatic
group
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127030070A
Other languages
English (en)
Korean (ko)
Other versions
KR20130051945A (ko
Inventor
제임스 알. 젤러
스티븐 피. 타니스
스콧 디. 라르센
티모티 파커
Original Assignee
씨리우스 테라퓨틱스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨리우스 테라퓨틱스, 엘엘씨 filed Critical 씨리우스 테라퓨틱스, 엘엘씨
Publication of KR20130051945A publication Critical patent/KR20130051945A/ko
Application granted granted Critical
Publication of KR101781665B1 publication Critical patent/KR101781665B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/51—Acetal radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896—Compounds having one or more Si-O-acyl linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
KR1020127030070A 2010-04-19 2011-04-18 티아졸리딘디온 화합물을 위한 신규한 합성법 Expired - Fee Related KR101781665B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32550210P 2010-04-19 2010-04-19
US61/325,502 2010-04-19
US32749810P 2010-04-23 2010-04-23
US61/327,498 2010-04-23
PCT/US2011/032822 WO2011133442A1 (en) 2010-04-19 2011-04-18 Novel synthesis for thiazolidinedione compounds

Publications (2)

Publication Number Publication Date
KR20130051945A KR20130051945A (ko) 2013-05-21
KR101781665B1 true KR101781665B1 (ko) 2017-09-25

Family

ID=44148625

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127030070A Expired - Fee Related KR101781665B1 (ko) 2010-04-19 2011-04-18 티아졸리딘디온 화합물을 위한 신규한 합성법

Country Status (15)

Country Link
US (1) US8937182B2 (enExample)
EP (1) EP2560956B1 (enExample)
JP (1) JP2013525355A (enExample)
KR (1) KR101781665B1 (enExample)
CN (1) CN102947269B (enExample)
AU (1) AU2011242956B2 (enExample)
CA (1) CA2796437C (enExample)
DK (1) DK2560956T3 (enExample)
ES (1) ES2610623T3 (enExample)
HU (1) HUE030263T2 (enExample)
MX (1) MX2012012092A (enExample)
NZ (1) NZ602883A (enExample)
PL (1) PL2560956T3 (enExample)
RU (1) RU2012148908A (enExample)
WO (1) WO2011133442A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
US8933240B2 (en) 2010-08-10 2015-01-13 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US20210038566A1 (en) 2018-02-08 2021-02-11 Enyo Pharma Use of modulators of neet proteins for the treatment of infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027798A1 (en) * 2000-04-24 2003-02-06 Pascal Druzgala Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2009038681A1 (en) * 2007-09-14 2009-03-26 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
ATE202352T1 (de) * 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
JPH07188227A (ja) * 1993-12-24 1995-07-25 Japan Tobacco Inc チアゾリジン誘導体及びオキサゾール誘導体
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
FR2817144B1 (fr) 2000-11-29 2003-01-03 Micro Mega Sa Sequence d'instruments canalaires pour l'execution d'un protocole operatoire d'endodontie
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
FR2861069B1 (fr) 2003-10-17 2005-12-09 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
JP2009530293A (ja) 2006-03-16 2009-08-27 メタボリック ソリューションズ ディベロップメント カンパニー チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
EP2001469B1 (en) * 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
EP2486926A1 (en) 2006-03-16 2012-08-15 Metabolic Solutions Development Company LLC Thiazolidinedione Analogues
EP2098517B1 (en) * 2006-12-01 2013-12-18 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
WO2008118327A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
MX2012012094A (es) 2010-04-19 2012-12-17 Metabolic Solutions Dev Co Llc Sintesis novedosa para compuestos de tiazolidinadiona.
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
US8933240B2 (en) 2010-08-10 2015-01-13 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027798A1 (en) * 2000-04-24 2003-02-06 Pascal Druzgala Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2009038681A1 (en) * 2007-09-14 2009-03-26 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same

Also Published As

Publication number Publication date
US8937182B2 (en) 2015-01-20
CA2796437C (en) 2018-09-11
ES2610623T3 (es) 2017-04-28
EP2560956A1 (en) 2013-02-27
CN102947269B (zh) 2015-11-25
CA2796437A1 (en) 2011-10-27
CN102947269A (zh) 2013-02-27
AU2011242956A1 (en) 2012-11-01
PL2560956T3 (pl) 2017-03-31
MX2012012092A (es) 2012-12-17
AU2011242956B2 (en) 2015-01-22
WO2011133442A1 (en) 2011-10-27
HUE030263T2 (en) 2017-04-28
DK2560956T3 (en) 2017-01-23
US20130204004A1 (en) 2013-08-08
HK1178155A1 (en) 2013-09-06
RU2012148908A (ru) 2014-05-27
NZ602883A (en) 2014-09-26
JP2013525355A (ja) 2013-06-20
KR20130051945A (ko) 2013-05-21
EP2560956B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
KR20130051944A (ko) 티아졸리딘디온 화합물을 위한 신규한 합성법
KR101781665B1 (ko) 티아졸리딘디온 화합물을 위한 신규한 합성법
KR101857307B1 (ko) 티아졸리딘디온 화합물의 합성법
KR101988203B1 (ko) 티아졸리딘디온 화합물의 신규한 합성법
HK1178155B (en) Novel synthesis for thiazolidinedione compounds
HK1181772A (en) Novel synthesis for thiazolidinedione compounds
HK1182099A (en) Synthesis for thiazolidinedione compounds
HK1182099B (en) Synthesis for thiazolidinedione compounds
HK1181385A (en) Synthesis for thiazolidinedione compounds
HK1181385B (en) Synthesis for thiazolidinedione compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230920

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230920